0001062993-22-002729.txt : 20220204 0001062993-22-002729.hdr.sgml : 20220204 20220204192852 ACCESSION NUMBER: 0001062993-22-002729 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220202 FILED AS OF DATE: 20220204 DATE AS OF CHANGE: 20220204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ortega-Valle Marta CENTRAL INDEX KEY: 0001908352 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39894 FILM NUMBER: 22595169 MAIL ADDRESS: STREET 1: C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC STREET 2: 200 BOSTON AVENUE, SUITE 3100 CITY: MEDFORD STATE: MA ZIP: 02155 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GreenLight Biosciences Holdings, PBC CENTRAL INDEX KEY: 0001822691 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 851914700 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 BOSTON AVENUE STREET 2: SUITE 3100 CITY: MEDFORD STATE: MA ZIP: 02155 BUSINESS PHONE: (617) 616-8188 MAIL ADDRESS: STREET 1: 200 BOSTON AVENUE STREET 2: SUITE 3100 CITY: MEDFORD STATE: MA ZIP: 02155 FORMER COMPANY: FORMER CONFORMED NAME: Environmental Impact Acquisition Corp DATE OF NAME CHANGE: 20200826 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0306 4 2022-02-02 0001822691 GreenLight Biosciences Holdings, PBC GRNA 0001908352 Ortega-Valle Marta C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC 200 BOSTON AVENUE, SUITE 3100 MEDFORD MA 02155 0 1 0 0 Chief Business Officer Stock Option (Right to Buy) 0.24 2022-02-02 4 A 0 29798 A 2022-06-08 Common Stock 29798 29798 D Stock Option (Right to Buy) 0.28 2022-02-02 4 A 0 105266 A 2023-12-13 Common Stock 105266 105266 D Stock Option (Right to Buy) 0.35 2022-02-02 4 A 0 106098 A 2025-07-22 Common Stock 106098 106098 D Stock Option (Right to Buy) 0.98 2022-02-02 4 A 0 247727 A 2030-09-24 Common Stock 247727 247727 D Stock Option (Right to Buy) 0.98 2022-02-02 4 A 0 259584 A 2030-12-01 Common Stock 259584 259584 D 100% of the shares subject to this option are fully vested and exercisable. This option was issued pursuant to the terms of a business combination agreement involving the Issuer and GreenLight Biosciences, Inc. in exchange for a comparable option previously issued by such company. 100% of the shares subject to this option are fully vested and exercisable. 100% of the shares subject to this option are fully vested and exercisable. 20% of the shares underlying the option vested or shall vest on September 24, 2021 and the remainder of the shares vested or shall vest in 48 equal monthly installments thereafter, starting October 24, 2021. 25% of the shares underlying the option vested or shall vest on December 1, 2021 and the remainder of the shares vested or shall vest in 36 equal monthly installments thereafter, starting January 1, 2022. /s/ David Kennedy, Attorney-in-fact 2022-02-04